Inflammatory biomarkers are not predictive of intermediate-term risk of ventricular tachyarrhythmias in stable CHF patients

Clinical Cardiology

Volumn 30, Issue 8, 2007, Pages 408-413

  Konstantino, Yuval ^a,b   Kusniec, Jairo ^a,b   Tamar, Reshef ^b,c   David Zadeh, Ofer ^d   Mazur, Alexander ^a,b   Strasberg, Boris ^a,b   Battler, Alexander ^a,b   Haim, Moti ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

^d BAR ILAN UNIVERSITY   (Israel)

Author keywords

Heart failure; Inflammatory biomarkers BNP; Ventricular tachyarrhythmias

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CARDIOVERSION; CHRONIC DISEASE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DEFIBRILLATOR; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; MALE; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TACHYCARDIA, VENTRICULAR; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FIBRILLATION;

EID: 34548159958     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20110     Document Type: Article

References (25)

1. Aukrust P, Damas JK, Gullestad L: Immunomodulating therapy: new treatment modality in congestive heart failure Review. Congest Heart Fail 2003;9:64-69
2. Paulus WJ: Cytokines and heart failure Review. Heart Fail Monit 2000;1: 50-56
3. Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future Review. Circ Res 2002;91:988-998
4. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, et al.: Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-3067
5. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, et al.: Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391-398
6. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, et al.: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-1593
7. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, et al.: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001;103:2055-9
8. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, et al.: Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004;147:931-938
9. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, et al.: C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005;112: 1428-1434
10. Alonzo-Martinez JL, Llorente-Diez B, Echegaray Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, et al.: C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002;4:331-336
11. Doust JA, Pietrzak E, Dobson A, Glasziou PP: How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005;330:625-633
12. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, et al.: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-2397
13. Watanabe J, Shiba N, Shinozaki T, Koseki Y, Karibe A, et al.: Prognostic value of plasma natriuretic peptide combined with left ventricular dimensions in predicting sudden death of patients with chronic heart failure. J Card Fail 2005;11:50-55
14. Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, et al.: Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005;149:1020-1034
15. Oseroff O, Retyk E, Bochoeyer A: Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol 2004;19:26-30
16. Eckardt L, Haverkamp W, Johna R, Bocker D, Deng MC, et al.: Arrhythmias in heart failure: current concepts of mechanisms and therapy. J Cardiovasc Electrophysiol 2000;11:106-117
17. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, et al.: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-1206
18. Kell R, Haunstetter A, Dengler TJ, Zugck C, Kubler W, et al.: Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. Eur Heart J 2002;23: 70-78
19. Marcucci R, Gori AM, Giannotti F, Baldi M, Verdiani V, et al.: Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006; 4:1017-1022
20. Rodriguez-Reyna TS, Arrieta O, Castillo-Martinez L, Orea-Tejeda A, Guevara P, et al.: Tumor necrosis factor alpha and troponin T as predictors of poor prognosis in patients with stable heart failure. Clin Invest Med 2005;28:23-29
21. Chirinos JA, Zambrano JP, Chakko S, Schob A, Veerani A, et al.: Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. Am J Cardiol 2005;95:88-90
22. Lamblin N, Mouquet F, Hennache B, Dagorn J, Susen S, et al.: High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 2005;26:2245-2250
23. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, et al.: Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005; 165:1304-1309
24. Manios EG, Kallergis EM, Kanoupakis EM, Mavrakis HE, Kambouraki DC, et al.: Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators. Chest 2006;128:2604-2610
25. Verma A, Kilicaslan F, Martin DO, Minor S, Starling R, et al.: Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006;92:190-195